Provided are nanobodies that bind human calreticulin, fusion proteins including the nanobodies, pharmaceutical compositions including the nanobodies or fusion proteins, and radioconjugates of the nanobodies or fusion proteins.

Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.

Cancer treatment methods using thermotherapy and/or enhanced immunotherapy are disclosed herein. One two-stage cancer treatment method comprises the steps of: (i) in a first stage, administering, to a patient with a metastatic malignancy, tumor-antibody-coated nanoparticles conjugated with one or more medications and/or one or more immune stimulators for attaching to circulating exosomes, extracellular vesicles, and/or circulating tumor cells, thus promoting a destruction of the circulating exosomes, extracellular vesicles, and/or circulating tumor cells by a cellular immune system of the patient; and (ii) in a second stage, treating a main tumor of the patient during the same session or during another session of therapy by administering the tumor-antibody-coated nanoparticles conjugated with the one or more medications and/or the one or more immune stimulators so as to stimulate the cellular immune response of the patient to destroy the main tumor.

Monoclonal antibodies to human tau aggregate, compositions comprising such tau antibodies, and methods of using such tau antibodies for the treatment of neurodegenerative diseases including Alzheimer's disease, Progressive Supranuclear Palsy and Pick's disease.

Provided herein are antibodies that specifically bind Centrin-1 and methods of making the same, for use the treatment, prevention, detection, imaging, and diagnosis of cancers including pancreatic and prostate cancer.

Provided herein, inter alia, are compositions and methods of using the same for detecting complement activation.

The disclosure pertains to conformational epitopes in A-beta, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.

The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease.

The disclosure pertains to epitopes identified in A-beta including conformational epitopes, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.

Methods for detecting -synuclein oligomers in vivo comprise administering an antibody to an individual suspected of carrying soluble -synuclein, wherein the antibody is produced from a stabilized soluble -synuclein oligomer and is capable of binding the stabilized soluble -synuclein oligomer, wherein the stabilized soluble -synuclein oligomer has a lower formation rate to a non-soluble aggregated form than a non-stabilized soluble oligomer of the -synuclein, and wherein the antibody is labelled with a detectable marker; and detecting the presence of any complex formed between the antibody and soluble -synuclein by detection of the marker.